| ‘N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS’[Eur Heart J (2013); 34 (6): 443–450] P Welsh, O Doolin, P Willeit, C Packard, P Macfarlane, S Cobbe, ... European Heart Journal 34 (15), 1094, 2013 | | 2013 |
| " Anti-inflammatory" drugs and their effects on type 2 diabetes KA Deans, N Sattar Diabetes technology & therapeutics 8 (1), 18-27, 2006 | 73 | 2006 |
| “Silent” diabetes and clinical outcome after treatment with contemporary drug-eluting stents: the BIO-RESORT Silent Diabetes study C von Birgelen, MM Kok, N Sattar, P Zocca, C Doelman, GD Kant, ... Cardiovascular Interventions 11 (5), 448-459, 2018 | 28 | 2018 |
| “The Times They Are A-Changin’” at Diabetes Care SE Kahn, CAM Anderson, JB Buse, E Selvin, SY Angell, VR Aroda, ... Diabetes care 46 (1), 3-5, 2023 | | 2023 |
| [LB. 03.08] SERUM CHLORIDE AND ADVERSE CARDIOVASCULAR EVENTS IN THE ANGLO SCANDINAVIAN CARDIAC OUTCOMES TRIAL (ASCOT) L McCallum, P Welsh, P Sever, N Sattar, S Padmanabhan Journal of Hypertension 35, e78-e79, 2017 | | 2017 |
| & Sperrin, M.(2018). Adiposity-Mortality Relationships in Type 2 Diabetes, Coronary Heart Disease and Cancer Subgroups in the UK Biobank, and Their Modification by Smoking … D Jenkins, J Bowden, H Robinson, N Sattar, R Loos, M Rutter | | |
| # 1701797 Waist-to-height ratio shifts over time in tirzepatide-treated participants–post hoc analysis in SURMOUNT-1 and SURMOUNT-2 B Tchang, N Sattar, J Dunn, XM Zhang, LE Garcia-Perez, H Wang, C Mast, ... Endocrine Practice 30 (5), S68-S69, 2024 | | 2024 |
| 019 Ethnic differences in type 2 diabetes risk markers in children in the UK are not explained by socio-economic status: Child Heart and Health Study in England C Thomas, C Nightingale, A Rudnicka, C Owen, N Sattar, D Cook, ... Journal of Epidemiology & Community Health 64 (Suppl 1), A7-A8, 2010 | | 2010 |
| 094. Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with RA (TRACE RA): A Randomized Trial in 2986 RA Patients GD Kitas, P Nightingale, J Armitage, N Sattar, JJF Belch, DPM Symmons Rheumatology 54 (suppl_1), i87-i87, 2015 | 8 | 2015 |
| 1-year outcomes of angina management guided by invasive coronary function testing (CorMicA) TJ Ford, B Stanley, N Sidik, R Good, P Rocchiccioli, M McEntegart, ... Cardiovascular Interventions 13 (1), 33-45, 2020 | 187 | 2020 |
| 1-year outcomes of angina management guided by invasive coronary function testing (CorMicA). JACC Cardiovasc Interv. 2020; 13: 33–45 TJ Ford, B Stanley, N Sidik, R Good, P Rocchiccioli, M McEntegart, ... | 3 | |
| 1.4-O8 Progression to diabetes in Indian and Pakistani adults with impaired glycaemia in central Scotland: follow-up by record linkage in the PODOSA trial (Prevention of … A Douglas, S Wild, G Cezard, J Gill, M Lean, J McKnight, N Sattar, ... The European Journal of Public Health 28 (suppl_1), cky047. 031, 2018 | | 2018 |
| 103 Routine assessment of iron status in all patients with heart failure may identify those at risk of developing anaemia CL Murphy, EJ Fitzsimons, AJ Jardine, N Sattar, JJV Mcmurray European Journal of Heart Failure Supplements 6, 24-24, 2007 | 16 | 2007 |
| 1123-P: Stress Cardiac Biomarkers and Adverse Cardiac Outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS) N Sattar, J Xu, J Butler, KW Mahaffey, W Shaw, N Rosenthal, DE Gutstein, ... Diabetes 69 (Supplement_1), 2020 | | 2020 |
| 114 Persistence of Haemoglobin Degradation Products within Infarct Scar Tissue after ST-elevation Myocardial Infarction: Incidence, Correlates and Implications for Left … J Carberry, D Carrick, C Haig, S Rauhalammi, N Ahmed, I Mordi, ... Heart 102 (Suppl 6), A81-A81, 2016 | | 2016 |
| 115 Persistence of Infarct Zone Oedema at 6 Months after Acute ST-elevation Myocardial Infarction: Incidence, Pathophysiology and Association with Left Ventricular Remodelling J Carberry, D Carrick, C Haig, S Rauhalammi, N Ahmed, I Mordi, ... Heart 102 (Suppl 6), A81-A81, 2016 | | 2016 |
| 119 Overview of insulin resistance and the metabolic syndrome N Sattar, B Mukhopadhyay Lipids and Atherosclerosis, 119-136, 0 | | |
| 12 Adjudicated myocarditis and multisystem illness trajectory in healthcare workers post-COVID-19 RA Sykes, AJ Morrow, A McConnachie, A Kamdar, C Bagot, HK Bayes, ... Heart 110 (Suppl 1), A5-A7, 2024 | | 2024 |
| 120-OR: Efficacy of Tirzepatide in Achieving the Composite Endpoints of Glycemic, Blood Pressure, and Lipid Goals in SURMOUNT-2 N SATTAR, AYY CHENG, I BENABBAD, C LEE, S KYOUNGAH SEE, ... Diabetes 73 (Supplement_1), 2024 | | 2024 |
| 1237-P: Proteomic Indicators of Metabolic Health in Diabetes and Social Vulnerability M SIMPSON, R OSTROFF, SA WILLIAMS, N SATTAR Diabetes 72 (Supplement_1), 2023 | | 2023 |
David PreissAssociate Professor, University of Oxford在 ndph.ox.ac.uk 的电子邮件经过验证
